Innovation builds the future! Genuine Biotech wins "Most Investment Potential Award" from Cailianpress

On December 29, the "2025 Cailianpress 8th Annual Investment Conference and USTC Silicon Valley Hard Science and Technology Investment Ecology Conference" was held in Hefei, Anhui Province, China. The conference gathered many outstanding enterprises, investment institutions, industry leaders, and scholars, focusing on the most cutting-edge market voices and industrial wisdom around the theme of hard science and technology, and jointly exploring the future development. During the conference, the "2025 Capital Market Most Valuable Influential List" was unveiled. Genuine Biotech won the "Most Investment Potential Award" for its outstanding performance and industry leadership.

This conference, initiated by Cailianpress, covered multiple dimensions such as "industry, enterprises, organizations, overseas expansion, and individuals of influence", and spanned the whole industry tracks such as technology, manufacture, finance, consumption, energy, and healthcare, aiming to bring together the benchmarking forces that truly drive innovation and shape the future in China's capital market. The "Most Investment Potential Award" focuses on enterprises that demonstrate strong momentum and long-term value in terms of technological breakthroughs, business models, and market prospects. The fact that Genuine Biotech stood out among many candidates fully reflects the high recognition of its development path and potential by the industry and the capital market.

As a biotechnology company driven by innovative R&D, Genuine Biotech is dedicated to innovative drugs for the treatment of viral infections, tumors, and cardiovascular diseases, focusing on unmet clinical needs and building unique R&D pipelines with international competitiveness. The Company has now established a mature and sustainable complete drug R&D system, and will continuously promote the transformation and implementation of innovative achievements based on several unique technology platforms. Its solid and accumulated experience in scientific research, clear development strategy, as well as independent manufacturing and commercialization capabilities form a solid foundation for the long-term value of the Company.

The award is not only a recognition of Genuine Biotech's past achievements, but also a positive expectation of its future growth space. In the context of accelerating industrial change, Genuine Biotech will continue committing to innovative R&D, and join hands with all sectors of the community to promote the transformation of innovation achievements, and contribute the scientific and technological strength to enhancing global health.